Incyte Corporation (INCY) Shares are Down -10.78%

Incyte Corporation (INCY) : During the past 4 weeks, traders have been relatively bearish on Incyte Corporation (INCY), hence the stock is down -4.3% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -10.83% relative to the S&P 500. The 4-week change in the price of the stock is -3.32% and the stock has fallen -10.78% in the past 1 week.

The stock has recorded a 20-day Moving Average of 6.96% and the 50-Day Moving Average is 2.87%. Incyte Corporation (NASDAQ:INCY): On Fridays trading session , Opening price of the stock was $81.08 with an intraday high of $81.48. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $80.5. However, the stock managed to close at $81.05, a loss of 0.20% for the day. On the previous day, the stock had closed at $81.21. The total traded volume of the day was 856,381 shares.


The company Insiders own 13.7% of Incyte Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -13.06% . Institutional Investors own 93.98% of Incyte Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -13.06%. Also, In the latest statement by the brokerage house, Barclays maintains its outlook on Incyte Corporation (NASDAQ:INCY). The current rating of the shares is Overweight, according to the research report released by the firm. The brokerage firm raises the price target from $85 per share to $100 per share. The rating by the firm was issued on August 10, 2016.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.